EGFR and neoplasm: Although several literature-based meta-analyses have been published on the clinical efficacy of early tumor shrinkage and depth of response in patients with metastatic CRC,13,24 to the best of our knowledge, this study represents the largest investigation to date using individual patient data to examine the association between early tumor shrinkage and depth of response with overall survival, PFS, and postprogression survival in the context of chemotherapy combined with anti-EGFR antibodies or bevacizumab, according to tumor sidedness in patients with RAS wild-type metastatic CRC.